PRODIGY® with HAVLOGEN®

Horses

Therapeutic Class

Equine Rhinopneumonitis Vaccine


Description
An inactivated, purified, concentrated, adjuvanted, tissue culture origin, Equine Herpesvirus EHV-1 vaccine.

Indications
For vaccination of healthy horses 6 months of age or older, as an aid in the prevention of abortion and respiratory disease associated with Equine Herpesvirus 1 infection.

Administration and Dosage
For pregnant mares administer a 2 mL dose intramuscularly during the 5th, 7th and 9th months of pregnancy. Three doses are essential for primary immunization. Maiden and barren mares housed or pastured with pregnant mares should be vaccinated on the same schedule. For primary immunization against respiratory disease administer three 2 mL doses intramuscularly at 4 to 6 week intervals. A 2 mL dose should be administered annually and at any time epidemic conditions exist or are reported and exposure is imminent.

Caution
Store at 35o to 45o F (2o to 7oC). Shake well before using. Use entire contents when first opened. Do not vaccinate within 21 days before slaughter. Local reactions may occur if this product is given subcutaneously. Inject deep into the muscle only. Anaphylactoid reactions may occur.

Antidote
Epinephrine. Neomycin, polymyxin B, and thimerosal added as preservatives.

Supplied
Code: 069141
10 X 2 mL (1 dose) sterile syringes per box, individually printed plastic bag with needle.
Code: 069142
20 mL (10 doses) vial.

Product Label(s) and MSDS

For more information about Merck Animal Health Products call 1-800-441-8272.